Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Thomas

Showing results (121-130 of 262) with videos related to

Pageof 27
Sort By:
The Journal of Biological Chemistry|April 23, 2004
Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activityXavier Thomas, Delphine Destoumieux-Garzón, Jean Peduzzi, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|April 18, 2002
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trialAmine Belhabri, Xavier Thomas, Eric Wattel, et al.
Hematology (Amsterdam, Netherlands)|June 19, 2010
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 scheduleOlfa Derbel, Giovanna Cannas, Quoc-Hung Le, et al.
Haematologica|March 7, 2007
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 studyXavier Thomas, Stefan Suciu, Bernard Rio, et al.
Blood|July 5, 2007
Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLsJulie Bergeron, Emmanuelle Clappier, Isabelle Radford, et al.
Blood|March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemiaJean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|September 28, 2004
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized studyXavier Thomas, Jean-Michel Boiron, Françoise Huguet, et al.
Blood|September 28, 2002
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Christophe Sagot, Nicolas Boissel, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 8, 2016
Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution ExperienceMaël Heiblig, Mohamed Elhamri, Isabelle Tigaud, et al.
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Pageof 27

Showing results (121-130 of 262) with videos related to

Sort By:
Pageof 27
The Journal of Biological Chemistry|April 23, 2004
Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activityXavier Thomas, Delphine Destoumieux-Garzón, Jean Peduzzi, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|April 18, 2002
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trialAmine Belhabri, Xavier Thomas, Eric Wattel, et al.
Hematology (Amsterdam, Netherlands)|June 19, 2010
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 scheduleOlfa Derbel, Giovanna Cannas, Quoc-Hung Le, et al.
Haematologica|March 7, 2007
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 studyXavier Thomas, Stefan Suciu, Bernard Rio, et al.
Blood|July 5, 2007
Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLsJulie Bergeron, Emmanuelle Clappier, Isabelle Radford, et al.
Blood|March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemiaJean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|September 28, 2004
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized studyXavier Thomas, Jean-Michel Boiron, Françoise Huguet, et al.
Blood|September 28, 2002
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Christophe Sagot, Nicolas Boissel, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 8, 2016
Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution ExperienceMaël Heiblig, Mohamed Elhamri, Isabelle Tigaud, et al.
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Pageof 27